

# Clinical Commissioning Policy Proposition:

Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (Adults)

Reference: NHS England 1692



## Prepared by NHS England Specialised Services Clinical Reference Group for Cardiothoracic Services

oraticon public consultation

## Contents

ntents	3
Executive Summary Equality Statement Plain Language Summary	4 4 4
	-
Introduction	6
Proposed Intervention and Clinical Indication	6
Definitions	8
Aims and Objectives	9
Epidemiology and Needs Assessment	9
Evidence Base	10
Proposed Criteria for Commissioning	17
Proposed Patient Pathway	19
Proposed Governance Arrangements	20
Proposed Mechanism for Funding	20
Proposed Audit Requirements	21
Documents That Have Informed This Policy Proposition	21
Date of Review	21
oral for pur	
	ItentsExecutive SummaryEquality Statement

## **1 Executive Summary**

#### **Equality Statement**

Promoting equality and addressing health inequalities are at the heart of NHS England's values. Throughout the development of the policies and processes cited in this document, we have:

- Given due regard to the need to eliminate discrimination, harassment and victimisation, to advance equality of opportunity, and to foster good relations between people who share a relevant protected characteristic (as cited under the Equality Act 2010) and those who do not share it; and
- Given regard to the need to reduce inequalities between patients in access to, and outcomes from healthcare services and to ensure services are provided in an integrated way where this might reduce health inequalities

#### Plain Language Summary

#### About

Atrial fibrillation (AF) is the most common cardiac arrhythmia (abnormal heart rhythm) seen in clinical practice. Some patients with AF may not experience symptoms relating to their arrhythmia whilst others may experience dizziness, shortness of breath or notice palpitations.

Due to the irregular contractions of the atrium (an upper chamber of the heart) in AF, blood is not effectively pumped out of the atrium and instead may pool and form clots (thrombus). The left atrial appendage (a small pouch/sac in the wall of the left atrium of the heart) is the site at which over 90% of these clots will occur. If a clot is then expelled from the heart it can enter the brain circulation, cause a blockage and lead to a disabling or even fatal stroke. AF is associated with a 5 times increased risk of stroke.

#### About current treatments

Treatment of AF patients with medication (oral anticoagulants or OACs) that slow or prevent the clotting of blood has been shown to reduce this risk of stroke. These medications are associated with the potential for severe bleeding complications. They would be unsuitable for patients with a history of severe haemorrhage or high bleeding risks. While these are the main considerations, they may be other reasons for unsuitability for OACs.

#### About the new treatment

Percutaneous occlusion of the left atrial appendage (LAAO) is aimed at closing off the left atrial appendage, thereby reducing the ability of clot formation and subsequent risk of a stroke.

#### What we have decided

NHS England has carefully reviewed the evidence to treat patients with non-valvular atrial fibrillation and absolute and relative contraindications to oral anticoagulants with percutaneous left atrial appendage occlusion. We have concluded that there is enough evidence to consider making the treatment available as an interim policy until further evidence is available. ASAP-TOO trial is due to report in 2023 and NHS England will review the policy following publication of the results.

oration

## 2 Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to routinely commission Left Atrial Appendage Occlusion for patients with non-valvular atrial fibrillation and relative or absolute contraindications to oral anticoagulation therapies.

This document also describes the proposed criteria for commissioning, proposed governance arrangements and proposed funding mechanisms.

For the purpose of consultation NHS England invites views on the evidence and other information that has been taken into account as described in this policy proposition.

A final decision as to whether Left Atrial Appendage Occlusion for patients with atrial fibrillation and absolute and relative contraindications to oral anticoagulation therapies will be routinely commissioned will made by NHS England following a recommendation from the Clinical Priorities Advisory Group.

## **3** Proposed Intervention and Clinical Indication

Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia (abnormal heart rhythm). The estimated prevalence in the general population is 1-2% and increases with age. Some patients with AF may not experience symptoms relating to their arrhythmia whilst others may experience dizziness, shortness of breath or notice palpitations. Due to the irregular contractions of the atrium in AF, blood is not effectively pumped out of the atrium and instead may pool and form clot/s (thrombus/thrombi). Hence the reason for stroke in AF is cardio-embolic. If a thrombus enters the cerebral circulation, it may cause occlusion and lead to a disabling or even fatal stroke. AF is associated with a 5 times increased risk of stroke which tend to be ischaemic. Strokes related to AF are associated with a higher mortality and morbidity when compared with non-AF strokes, emphasizing the need for more effective stroke prevention in these patients. There is a clear relationship between the CHADS2 score, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and stroke rate and also the HAS-BLED score for bleeding risk that influence decisions for anticoagulant treatment choice.

Prospective and randomized studies show that oral anticoagulation significantly reduces the risk of thromboembolism and stroke by 68%. However, this treatment is underutilized in up to 40-50% of patients with AF due to poor patient compliance, contraindications and potential bleeding complications. Oral anticoagulation is aimed at reducing this risk of stroke by preventing thrombus formation but this in turn means that medications like Warfarin are associated with the potential for severe haemorrhagic complications including intracerebral haemorrhage. Even with the newer direct oral anticoagulants (DOACs), the overall incidence of major bleeding may not be less than vitamin K antagonists (VKAs), however intracranial haemorrhage (ICH) rates may be lower while gastrointestinal bleeding may be more pronounced.

Hence current oral anticoagulant therapy options would likely be unsuitable for patients with a history of or high risk of major or life threatening haemorrhage e.g. intracranial or gastroenterological haemorrhage. A history of spontaneous or OACassociated intracranial haemorrhage increases the risk of recurrent haemorrhage and devastating clinical consequences. Consequently, these patients are currently unprotected from the risk of stroke.

The left atrial appendage (LAA) is a small pouch/sac in the wall of the left atrium of the heart. It is recognised as a site where pooled blood may form and enable thrombus formation during the irregular contractions in non-valvular AF. The LAA is the most common site of thrombi (> 90%). Percutaneous occlusion of the left atrial appendage (LAAO) is aimed at closing off the appendage, thereby reducing the ability of thrombus formation and risk of thromboembolism.

The procedure is usually carried out under general anaesthetic with the use of echocardiographic and fluoroscopy guidance. It requires placement of a catheter in the right femoral vein, followed by puncture of the inter-atrial septum of the heart. The LAA can then be accessed and a device is then inserted and expanded to fill the site and close off the appendage. The duration of the procedure is approximately one hour.

NICE has published Interventional Procedure Guidance (IPG349) on its use which should be limited to units with on-site cardiac surgery. NICE guidance on the management of AF (CG180) recommends the consideration of LAAO in patients for whom oral anticoagulation therapy would be indicated based on stroke risk but in whom oral anticoagulants are contraindicated or not tolerated.

This policy describes the rationale for the use of LAAO for patients with non-valvular AF and relative or absolute contraindications for oral anticoagulation and clinical and research governance requirements for future monitoring.

## **4** Definitions

Atrial fibrillation

Atrial fibrillation is a heart condition that causes an irregular heartbeat. It results from loss of co-ordinated contraction of the two atria – the upper receiving chambers of the heart. Non-valvular AF is AF which occurs in the absence of rheumatic mitral valve disease or a metallic mitral prosthesis.

Cardio-embolic

A cardio-embolic stroke is one that results from debris or clot in the heart moving into the circulation and blocking a blood vessel supplying brain tissue.

Ischaemic stroke

A stroke due to blockage of an artery that supplies blood and oxygen to part of the brain. When this blockage is due to a clot that has travelled from the heart it is called cardio-embolic or thromboembolic

Left atrial appendage

The left atrial appendage is a small pouch in the left atrium. It is a site where blood clots predominantly form in atrial fibrillation

Haemorrhagic complications

This is a complication involving a bleeding event.

## 5 Aims and Objectives

This policy proposition considered: The clinical criteria under which NHS England will routinely commission the LAAO procedure for patients with non-valvular AF and relative or absolute contraindications to anticoagulation

The objectives were to:

- Determine the clinical effectiveness and safety of LAAO in the prevention of stroke in patients with AF at high risk of stroke and who have relative or absolute clinical contraindication/s to the use of oral anticoagulant therapies.
- Determine the patient eligibility criteria for the LAAO device, ensuring the best clinical and cost-effective use and taking account of patient risk stratification
- Ensure robust monitoring and follow up arrangements to enable audit of stroke/other thromboembolic event rate and procedure/device related complications.

## 6 Epidemiology and Needs Assessment

The prevalence of diagnosed AF is 1.7% (QOF Report, 2015-16). About 83% of patients with CHADS2 (old scoring system) of >1 are eligible for stroke prevention treatment, usually with oral anticoagulants.

The number of patients with contraindications will vary widely depending on criteria threshold. Many patients are not treated, but reasons for this may include physician or patient decisions or error rather than a formal contraindication. It is estimated that 6% of diagnosed AF patients have contraindications to OAC (Adderley N et al. 2017).

Hence it can be estimated that in a population of 53 million (England) there are 800,000 diagnosed with AF of which 664,000 have a risk profile requiring treatment and 40,000 have contraindications to OAC. However many patients will be near end of life or have comorbidities that make LAAO unsuitable, or may decide they don't want the treatment.

It is estimated that eventually 10% of LAAO-eligible patients will be referred for possible LAAO, as referral networks become established, but this will take >5 years.

If approved, it is estimated that initial case volume would be 400 per annum, building up to 1000 per annum in 5 years' time.

## 7 Evidence Base

NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of this treatment for the indication.

#### SUMMARY OF EVIDENCE REVIEW

The following summary is abstracted from the externally commissioned evidence review by NICE, for the purposes of the policy proposition. For full details of the evidence and the references, please refer to the full evidence review.

Fourteen studies (presented in 20 publications) met the inclusion criteria for **clinical effectiveness and adverse events** (Berti et al. 2016, Betts et al. 2017, Boersma et al. 2016a, Boersma et al. 2016b, Figini et al. 2017, Koskinas et al. 2016, Lopez Minguez et al. 2015, Reddy et al. 2013, Santoro et al. 2016, Seeger et al. 2016, Tzikas et al. 2016, Bergmann et al. 2017, Boersma et al. 2017, Freixa et al. 2016, Huang et al. 2017, Lempereur et al. 2017b, Meerkin et al. 2013, Murarka et al. 2017, Saw et al. 2017, Tzikas et al. 2017). All of these studies were registry or observational studies; no randomised controlled studied were identified that met the inclusion criteria.

Two further studies informed our analysis of **cost effectiveness** (Panikker et al. 2016, Reddy et al. 2016).

Please note this evidence review was restricted to peer-reviewed publications with studies of any design as long as they had a sample size of 100 or above, as well as registry studies that included over 50% patients for whom anticoagulation therapy was contraindicated. Thus, studies with fewer than 100 participants or those only published in conference abstracts were not eligible for inclusion (see section 9).

#### Clinical effectiveness and adverse events:

The 14 included registry or observational studies ranged in size from 100 to 1,047 patients. These studies reported on various procedure and device-related adverse events (typically  $\leq$  7 days), as well as follow-up complications and adverse events (with a follow-up duration that ranged from 210.3 [SD 182.2] days to 30 [SD 12] months [264 patient-years] across the studies).

These studies show that LAAO with various devices (Watchman, ACP, Amulet) is associated with a moderate number of peri-procedural complications and low adverse events. The most frequent peri-procedural events were minor pericardial effusion and bleeding. The most frequent complications associated with LAAO devices in the long-term included stroke, bleeding, device-related thrombus and leaks. The percentages of patients with various complications and adverse events is described in detail in Section 4 below.

In terms of stroke, the percentage of patients who experienced peri-procedural stroke was reported in eleven studies and ranged from 0% to 1.2% across these studies. Three studies reported on ischaemic stroke, which ranged from 0% to 1%. The remaining studies did not report on peri-procedural stroke.

All-cause stroke or embolism at follow-up was reported in six studies and ranged from 0% (reported at a mean follow-up of  $210.3 \pm 182.2$  days) to 4.5% (reported at a mean follow-up of  $30 \pm 12$  months). Rates ranged from 1.6 per 100 patient-years to 2.3% per year. Eight studies reported on ischaemic or haemorrhagic stroke. The percentages of patients with ischaemic stroke ranged from 0% (reported at a mean follow-up of 448 (167-793) days) to 2% (reported at a mean follow-up of 400 days). Rates of ischaemic stroke ranged from 0.57 per 100 patient-years to 2.2% per year and rates of haemorrhagic stroke ranged from 0.28 per 100 patient-years to 0.6% per year.

Many of the authors of these registry and observational studies concluded that LAAO appeared to be safe and effective in patients for whom anticoagulation therapy is contraindicated. However, given that these studies are inherently limited by the lack of a control group and had other methodological issues, the results presented by the study authors (as summarised in this evidence review) should be considered with caution and need to be confirmed with data from randomised controlled trials.

#### Cost-effectiveness:

Results from both studies suggest that LAAC provides long-term clinical and economic benefits when compared with aspirin; one study (Panikker et al. 2016) found that LAAO was also cost saving after year 7 compared with no therapy.

The Panikker (2016) study was a high quality cost study set in England, with good internal validity but poor external validity. The second, slightly weaker study, set in Germany, also lacked external validity (Reddy et al. 2016).

#### CONCLUSIONS FROM THE EVIDENCE REVIEW

The evidence review based on 14 registry/observational studies, suggests that LAAO in patients contraindicated to oral anticoagulants appears to be safe and effective. All of these studies are registry or observational studies covering a total population of 4200 patients. Two of the studies are very large and include over a thousand patients each (EWOLUTION, ACP). Arguably they are inherently limited by the lack of a control group. Hence any relevant comparisons of outcomes can only be made with historical data.

Further research from RCTs will be needed to confirm the current results of these registry studies. Key research findings include the following:

- The most frequent clinical indications for LAAO in patients at high risk of stroke/thromboembolic events included a history of major bleeding events, a high risk/predisposition to bleeding and secondary prevention following occurrence of significant thromboembolic events on OACs.
- Procedural success for the LAAO device was high and ranged from 88.3% to 100%.
- The devices most researched were the Watchman and the Amplatzer.
- Mean age of patients ranged between 64 to 77 years, and the majority

of patients were males. Where reported, the mean  $CHA_2DS_2$ -VASc score ranged between 3.6 (SD 1.6) and 4.6 (SD 1.4), and the mean HAS-BLED score ranged between 2.3 (SD 1.2) and 4.2 (SD 1.3).

- Peri-procedural and follow-up rates of thromboembolic events (stroke,TIA, systemic embolism) following LAAO appeared to be low.
- Rates of ischaemic stroke after LAAO were reduced to 0 2.0% a year. In the EWOLUTION Registry one year follow up, the rate of ischaemic stroke was 1.1 %, whereas the expected incidence of an ischaemic stroke or thromboembolic (stroke/TIA/peripheral embolism) event with a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 4 from historical data was 6.8% to 9.3% (Friberg et al. 2012.
- Death rates on followup could be up to 12%. However this may reflect the advanced age and other co-morbidities characteristics of the population implanted. This emphasises the importance of patient selection.
- There is a risk of bleeding circa 5% seen both peri-procedurally and during follow-up. This may reflect the relative background bleeding risk. In the two largest registries the risk of major bleeding was half this figure.
- Procedure and device-related complications included pericardial effusion, cardiac tamponade, air embolism, device thrombosis and leaks. Their individual frequencies were low and ranged from 0-3% a year. The reported frequency of device-related thrombus and leaks tended to be higher.
- There is beneficial evidence of a learning curve on the improvement of clinical outcomes. Overall, procedural success and safety increased with operator and centre experience.

#### SUMMARY OF COMMISSIONING THROUGH EVALUATION

The Commissioning through Evaluation (CtE) scheme for LAAO commenced on 1/10/2014 and ran for two years. It was a procedural registry with no comparator arm. Data was collected prospectively and patients were followed up for two years. Ten specialised cardiology and cardiac surgery centres participated. The evaluation was carried out by NICE in collaboration with the Cardiology CtE Steering Group which is a subgroup of the Cardiothoracic CRG. The latter with NICOR was responsible for the design and methodology.

On completion of the CtE, 571 LAAO procedure records were extracted, of which 46 patients did not meet the eligibility criteria and were excluded. 525 were available for analysis.

The aim of the CtE was to generate new evidence from real world acute clinical settings to enable a judgement on clinical and cost–effectiveness of LAAO in the identified population.

#### <u>Results</u>

#### **Risk Profile of Patients**

The patients in the CtE Registry had a median  $CHA_2DS_2$ -VASc score of 4 and median HASBLED score of 4. This is comparable with the other registries median  $CHA_2DS_2$ -VASc scores ranging from 4.2- 4.4. However the HASBLED scores for the latter were lower ranging from 2 to 3.3.

#### Success Rates:

#### Short -term

Technical success rates reported were 93.6% (95% CI 91.1% to 95.6%). Procedural success (defined as technical success in the absence of major complication) was reported as 89.0% (95% CI 86.0% to 91.6%). 99.3% had no or minor peri- device leak). Only two patients had a major leak. Clinical failure (device not implanted, large leak, neurological event before discharge) was reported in 9.1%. There was an in hospital major complication rate of 5.5%. The rate of procedural mortality was low (1%) with a reported neurological event rate of 0.8%. These outcomes were consistent with the published literature.

#### Medium --term

During follow-up 25 patients died – 19 of these 25 deaths were unrelated to the procedure or its indication. 19 patients had a neurological event during follow-up. 10 patients had ischaemic neurological events, giving a rate of 2.6 per 100 patient years. CtE did not provide any evidence for additional safety concerns.

#### Reduction in risk of stroke/embolic clinical events

Most patients in the CtE (circa 300) had a  $CHA_2DS_2$ -VASc score between 3 and 6, with 85 between 2-3. The median  $CHA_2DS_2$ -VASc score was 4 with a predicted risk of a thromboembolic event of 6.7% to 9.3% per year. This can be compared with the actual CtE incidence of 2.6% per year.

#### Length of Stay

This was a median of 1 overnight stay, However nearly a quarter of procedures resulted in an extended length of stay of  $\ge 2$  nights.

#### <u>QOL</u>

Quality of life (QoL) was measured at baseline and at follow up (6 weeks, 6 months, 1 year and 2 years) using the EuroQol system (EQ-5D-5L), converted to utility scores. The median baseline utility was 0.82. This improved to 0.85 at both 6 weeks and 6 months and reduced slightly to 0.84 at one and two years. These changes were not statistically significant. However the domain that demonstrated the greatest benefit from the procedure was a reduction in anxiety and depression.

#### Long term cardiac complications (e.g. penetration of arterial/atrial walls).

There were none noted in the CtE. Whilst this has to be noted in the context of the limited follow–up, this finding is consistent with the literature.

#### Reasons (and demand) for LAAO treatment

Just under a quarter of patients had previous bleeding without anticoagulant therapy. Nearly 60 percent had previous bleeding with anticoagulant therapy. 7.1 % were at risk of severe bleeding. These three categories amounted to 88% of requests. These categories equalled 83% in another UK registry by Betts. Other reasons included intolerance (majority)/poor control) of oral anticoagulants; primary or secondary prophylaxis and patient preference.

The associated literature review suggested that 2% of patients with AF had an absolute contraindication to warfarin use, with 60% having a history of ICH. Another study showed that 13% of patients eligible for oral anticoagulation had a major

#### contraindication to Warfarin.

#### LAAO Devices used

Thirty eight (38%) percent of devices used were Watchman with the Amplatzer Amulet accounting for 47%. The Amplatzer cardiac plug was used in 35 (8%) cases. There were no significant differences seen between devices in terms of superior technical or procedural success or death and neurological events.

#### Sub-group differences

No significant differences for outcomes were seen for age or gender,

#### Conclusions from CtE

- The CtE population reflected a population at high risk of stroke and bleeding and characteristic of other patients in the representative registries.
- Patients in the CtE registry had a median CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 4.
- Technical success rates (93.6%) and procedural success rates (89%) accorded with published data (despite inconsistent definitions and the early learning curve effect for several UK centres).
- The crude event rate for ischaemic stroke was 2.6 events per 100 person years. The median CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 4 which in a series of 180,000 patients without oral anticoagulation led to a thromboembolic event rate of 6.7 7.8 per 100 patients per year (Friberg et al.2012). This can be compared with the actual CtE achieved incidence of 2.6 thromboembolic events (95% Cl 1.3 -4.8) per 100 patients a year. The latter can also be compared with a historical expected adjusted stroke and thromboembolism risk of 9.3% at one year follow up (ESC Guidelines. 2012).
- Hence LAAO within the CtE was associated with a decreased risk of an ischaemic event compared with historical epidemiological data.
- The vast majority of reasons for undertaking LAAO were related to a history or risk of severe bleeding. Patients in the CtE registry had a relatively high risk of bleeding as measured by the median HAS BLED score of 4.

## 8 Proposed Criteria for Commissioning

Treatment with LAAO will be routinely funded in the circumstances outlined below:

#### **Eligibility Criteria**

#### Inclusion

Patients with non-valvular Atrial Fibrillation with a high thromboembolic risk

(CHA2DS2-VASC score of 2 or greater) and with physician-assessed

contraindications to OAC (both VKAs and NOACs), such as:

1. Patients with a history of severe/major haemorrhage such as intracranial or major gastrointestinal bleeding in whom further oral anticoagulation is likely to lead to a recurrent bleed

2. Patients with a similarly high risk of bleeding or predisposed to bleeding such as blood dyscrasias.

3. Patients with documented issues of severe intolerance to anticoagulation therapy.

4. Patients with a Rockwell frailty score (CHSA) of ≤6.

5. Patients with a high stroke risk who have suffered a thromboembolic event/ischaemic stroke despite OAC i.e failed therapy.

NB: The cut-off of  $\geq 2$  and not higher has been chosen to be consistent with NICE Guidance CG180 and to prevent patients who have a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of between 2-3 of remaining unprotected and at risk of stroke if OACs are contraindicated in their case).

For the consideration of LAAO, it is important that a comprehensive patient screen and risk assessment takes place. Patient selection procedures should take into account the following:

 The CHA<sub>2</sub>DS<sub>2</sub>-VASc score for estimated annual stroke risk and the HAS – BLED score which estimates annual bleeding risk (A HAS-BLED score ≥ 3 = a high bleeding risk). The CHA<sub>2</sub>DS<sub>2</sub>-VASc and the HAS-BLED scores complement each other when assessing the patient, as the latter additionally takes into account drugs, alcohol, labile INRs and bleeding whereas the former takes into account congestive heart failure, vascular disease, female sex and diabetes. These risk factors are in addition to age, sex, stroke and hypertension which are common to both scores.

- The HASBLED score gives a measure of a given patient's bleeding risk. It is anticipated that most patients who are considered for LAAO will have a HASBLED score above 2. The HASBLED score will be recorded in any National Registry. Need for anticoagulation per se however is based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 2 or greater and contraindication to anticoagulation will be the primary driver for considering possible LAAO.
- Percutaneous LAAO should be undertaken only in surgical cardiothoracic units. Operators (interventional or electrophysiological) and Echocardiographers need relevant training and expertise.
- Centres which are beginning a programme of LAAO, or are using a new device, should have relevant training and proctoring in the technique and the device use. This should include off-site training where provided by a company, and on-site proctoring until the operators are trained.
- Given that the benefit of left atrial appendage occlusion accrues over time, it is not expected that patients with a life expectancy of less than 3 years will be selected for LAAO
- Frailty score measurements eg KATZ, assessment of comorbidities, measurement of impaired organ function (renal, kidney etc) should be undertaken to inform patient selection, which should be based on expected prospective Quality of life and longevity. LAAO should not be used as a salvage therapy but only in circumstances where patients are best able to attain maximum and long term benefit from a reduction in ischaemic strokes and mortality.

#### • Anti-Thrombosis Protocols

Patients undergoing LAAO will be expected to be assessed for single or dual antiplatelet therapy for a minimum of six months following implant, taking into account their individual clinical circumstances/risk profile and manufacturers advice.

#### Exclusion criteria:

- Life expectancy less than 3 years.
- Left atrial appendage thrombus visualised.
- Valvular atrial fibrillation (i.e rheumatic mitral stenosis, mechanical mitral valve).
- Other indications for long-term or lifelong OAC—mechanical prosthetic valve, pulmonary embolism and deep vein thrombosis, thrombi in the left atrium or ventricle.
- Contraindications for transseptal catheterisation—left atrial thrombus or tumour, active infection.
- Patients clinically eligible and suitable for oral anticoagulants.
- Low risk for stroke  $CHA_2DS_2$ -VASc <2.

## 9 Proposed Patient Pathway

Consideration of which patients to refer:

Patients are likely to be referred via specialist services rather than by general practitioners. Patients will have been seen usually by a stroke physician, care of the elderly physician, general medical physician, or cardiologist.

Patients for this therapy will be elective, not urgent or emergent. Referral will be by letter or electronic means to the relevant cardiologist who will see the patient in clinic and discuss the potential risks and benefits of LAAO.

Pre-procedure investigations may include echocardiography or CT, or none.

Patients will be admitted for the procedure on the day, or the day before. The procedure will usually be done under general anaesthesia with echocardiographic control.

Patients will need an echocardiogram before discharge, to ensure that there is no significant pericardial effusion, or device embolization. Patients are usually discharged the next day, on an appropriate anti-thrombotic regimen treatment for up to six months to cover the period of endothelialisation of the device.

## **10 Proposed Governance Arrangements**

It is anticipated that sites will produce information leaflets (clinical indications, clinical benefits, complications, need for follow up, current evidence base and its limitations) for patients about left atrial appendage occlusion. Alternatively implanting sites will have information available via website.

Subsequent to the acute period (0-7days), follow-up will likely be in the centre which undertook the procedure. It is anticipated that patients will be seen at least once thereafter. Annual monitoring by the main treatment centre will take place until the RCTs report in 2023 and the policy is reviewed.

A National Registry will be set up to record procedural outcomes with left atrial appendage occlusion. Definitions for clinical and safety outcomes will need to be agreed and standardised with other registries to ensure comparability of outcome data. Submission of data to this database will be mandatory for all procedures undertaken. Linkage with other databases for follow-up and with the Medical Research Information Service is encouraged. The National Registry will draw on the data-fields already present during the Commissioning through Evaluation program, and will standardise these. Funding for the National Registry should be agreed for clinical and research governance assurance. NICE, NCAP, HQIP, NICOR, BCIS/HRS, NHSE would all be expected to have a stake.

The use of LAAO will subject to the NHS England prior approval system.

A suspected problem ('adverse incident') with the medical device should be reported using the Yellow Card Scheme as soon as possible at the following link: <u>https://www.gov.uk/report-problem-medicine-medical-device</u>

## **11 Proposed Mechanism for Funding**

The device is excluded from the national tariff and will be funded by pass through payments made against invoices raised by provider Trusts or through the high costs device programme.

The procedure is included in tariff and will be funded through the routine contract procedures. A specific code for LAAO (K62.5 Percutaneous transluminal occlusion

of left atrial appendage) maps to HRG 4+ EY22.

## **12 Proposed Audit Requirements**

Centres should undertake an annual audit of their LAAO programme, reporting efficacy and safety outcomes within the clinical governance structure of their hospital and network. They should benchmark themselves against existing and developing regional, national and international data. Audits should cover referral, patient selection, procedure indications, method of anaesthesia, duration of hospital stay, number of devices per patient, and peri-procedural complications. Complications (including time of occurrence) to be monitored would include strokes/TIAs/embolic events, bleeding, device embolization, air –embolism, pericardial effusion +/- cardiac tamponade +/-periocardiocentesis, all cause/ cardiovascular, procedure- related deaths.

## **13 Documents That Have Informed This Policy Proposition**

This document updates and replaces Clinical Commissioning Policy Statement: Left Atrial Appendage (LAA) Occlusion April 2013 Reference: NHSCB/A09/PS/c. LAAO is not routinely commissioned for all other indications.

See references

## 14 Date of Review

This document will lapse upon publication by NHS England of a clinical commissioning policy for the proposed intervention that confirms whether it is routinely or non-routinely commissioned. The Policy will be reviewed at the latest following the publication of the RCTs in 2023.

## **15 References**

- 1. Quality and Outcomes Framework- Prevalence, Achievements and Exceptions Report. England, 2015-16.
- 2. Adderley N, Ryan R, Marshall R. The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of

primary care data in the UK. Br J Gen Pract 2017; DOI: <u>https://doi.org/10.3399/bjgp17X691685</u>

- 3. Commissioning through Evaluation (CtE) Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism- (NYEAC 2017)
- 4. NHS England. Evidence review: Clinical and Cost Effectiveness and Adverse Events Associated with Left Atrial Appendage Occlusion in Patients Contraindicated to Anticoagulation therapy- (YHEC 2017)
- Bergmann MW, Betts TR, Sievert H, et al. (2017) Safety and efficacy of early anticoagulation drug regimens after Watchman left atrial appendage closure: three month data from the EWOLUTION prospective,multicentre,monitored international Watchman LAA closure registry. *Eurointervention* 13(7),pp.877-884.
- 6. Berti S, Pastormerlo LE, Rezzaghi M, et al. (2016) Left atrial appendage occlusioin in high-risk patients with non-valvular atrial fibrillation. *Heart* 102(24),pp. 1969-1973.
- 7. Betts TR, Leo M, Pannikar S, et al. (2016) Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicentre registry. Catheterisations and Cardiovascular Interventions 89(3),pp.484-492.
- Boersma LV, Ince H, Kische S, et al. (2017) Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with ot without contraindication to oral anticoagulation: 1-Year follow-up outcome date of the EWOLUTION trial. *Heart Rhythm* 14(9),pp. 1302-1308.
- Boersma LV, Schmidt B, Betts TR, et al. (2016a) Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *European Heart Journal* 37 (31),pp. 2465-74.
- 10. Boersma LV, Schmidt B, Betts TR, etal. (2016b) EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. *Catheterization and Cardiovascular Interventions* 88 (3), pp. 460-5.
- 11. Figini F, Mazzone P, Regazzoli D, et al. (2017) Left atrial appendage closure: A single center experience and comparison of two contemporary devices. *Catheterization and Cardiovascular Interventions* 89(4), pp. 763-772.

- 12. Freixa X, Llull L, Gafoor S, et al. (2016) Characterization of Cerebrovascular Events After Left Atrial Appendage Occlusion. *American Journal of Cardiology* 118 (12),pp. 1836-1841.
- 13. Huang W-P, Zhang Y-H, He L, et al. (2017) Efficacy and Safety of the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Chinese Patients with Nonvalvular Atrial Fibrillation: A Single-center, Prospective, Observational Study. *Chinese Medical Journal* 130 (4),pp. 434-438.
- 14. Lempereur M, Aminian A, Freixa X, et al. (2017a) Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. *Catheterization & Cardiovascular Interventions* 90(5),pp. E111-E121.
- 15. Lempereur M, Aminian A, Freixa X, et al. (2017b) Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Previous Major Gastrointestinal Bleeding (from the Amplatzer Cardiac Plug Multicenter Registry). *American Journal of Cardiology* 120(3),pp. 414-420.
- 16. Lempereur M, Legrand V, Martinez C, et al. (2016a) Device-associated thrombus formation after LAA closure: A systematic review of events reported with the Watchman Device, the Amplatzer Cardiac Plug and the Amulet (conference abstract). *EuroIntervention* Abstracts EuroPCR 2016, pp. 331.
- 17. Lempereur M, Legrand V, Martinez C, et al. (2016b) Device-associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the watchman, the amplatzer cardiac plug and the amulet (conference abstract). *Catheterization and Cardiovascular Interventions* 87(S2),pp. S147.
- 18. Lopez Minguez JR, Asensio JM, Gragera JE, et al. (2015) Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure. *Heart 101*(11),pp. 877-83.
- 19. MeerkinD, Butnaru A, Dratva D, et al. (2013) Early safety of the Amplatzer Cardiac PlugTM for left atrial appendage occlusion. *International Journal of Cardiology* 168(4),pp. 3920-5.
- 20. Murarka S, Lazkani M, Moualla S, et al. (2017) Left atrial anatomy and patient-related factors associated with adverse outcomes with the watchman device a real world experience. *Journal of Interventional Cardiology* 30(2),pp. 163-169.
- 21. Reddy VY, Mobius-Winkler S, Miller MA, et al. (2013) Left atrial appendage closure with the Watchman device in patients with a contraindication for oral

anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *Journal of the American College of Cardiology* 61(25),pp. 2551-6.

- 22. Santoro G, Meucci F, Stolcova M, et al. (2016) Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. *EuroIntervention* 11(10),pp. 1188-94.
- 23. Seeger J, Bothner C, Dahme T, et al. (2016) Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. *Clinical Research in Cardiology* 105(3),pp. 225-9.
- 24. Tzikas A, Freixa X, Llull L, et al. (2017) Patients with intracranial bleeding and atrial fibrillation treated with left atrial appendage occlusion: Results from the Amplatzer Cardiac Plug registry. *International Journal of Cardiology* 236,pp. 232-236.
- 25. Tzikas A, Shakir S, Gafoor S, et al. (2016) Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. *Eurointervention* 11(10),pp. 1170-9.

## **16 Glossary**

**Atrium** – The heart is divided into four chambers that are connected by heart valves. The upper two heart chambers are called atria. Atria are separated by an interatrial septum into the left atrium and the right atrium.

CHADS2 score - Estimates stroke risk in patients with atrial fibrillation.

CHA2DS2-VASc score - Calculates stroke risk for patients with atrial fibrillation.

**Commissioning through Evaluation (CtE)** – An NHS England programme that enables a limited number of patients to access treatments that are not funded by the NHS, but nonetheless show significant promise for the future, while new clinical and patient experience data are collected within a formal evaluation programme.

**Femoral vein** - The femoral vein is located in the upper thigh and pelvic region of the human body.

Fibrin - Is a protein that is essential for proper blood coagulation.

Gastroenterological - Of the digestive system.

**HAS-BLED** – The score for Major bleeding risk estimates risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care.

Haemorrhagic - Bleeding or the abnormal flow of blood.

**Intracerebral Haemorrhage (ICH)** - Is a type of stroke caused by bleeding within the brain tissue itself.

Intracranial - Within the skull.

Direct Oral Anti Coagulant medication (DOACs) – a new oral anticoagulant.

Occlusion - The blockage or closing of a blood vessel or hollow organ.

**Oral Anti Coagulant (OAC)** - A substance that slows or prevents the clotting of blood.

Percutaneous - Performed through the skin.

**Quality of Life (QOL)** - Is the perceived quality of an individual's daily life, that is, an assessment of their well-being or lack thereof.

**Relative absolute and contraindications for anticoagulation** – A reason for not giving blood thinning medicines which is so overpowering or carries such a grave risk that its performance would be reasonably regarded as constituting malpractice.

Stenosis - an abnormal narrowing or contraction of a body passage or opening.

Thromboembolic - Formation in a blood vessel of a clot (thrombus) that breaks loose and is carried by the blood stream to plug another vessel.

Transseptal catheterisation - A method used to measure the left atrial and left onsuitaino ventricular pressure.

END